Revelation Biosciences (REVB) stock ticks up premarket after FDA lays out Gemini trial path
Revelation Biosciences shares rose about 2% premarket after an SEC filing showed FDA agreement on a single adaptive Phase 2/3 trial for its Gemini program in acute kidney injury. The company said strong results from roughly 300 patients could support a U.S. approval filing. Shares last traded near $0.85. Investors remain focused on trial timing and the firm’s $12.7 million cash position.
